ReportGem ReportGem 中文

REAL-TIME GLOBAL RESEARCH

Expert discussion + Veradermics CEO Q&A on VDPHL01 in Female Pattern Hair loss

Published: 2026-06-24Institution: CitiCompany / ticker: MANEPages: 2Original language: EnglishEvidence page: 1
MANE coverageCiti research

Research evidence excerpt

Expert discussion + Veradermics CEO Q&A on VDPHL01 in Female Pattern Hair loss

Event Replay

24 Jun 2026 12:42:45 ET │ 2 pages

Expert discussion + Veradermics CEO Q&A on

VDPHL01 in Female Pattern Hair loss

Video Webcast

Geoff Meacham, Ph.D.

+1-404-443-4701

geoffrey.meacham@citi.com

Speakers Reid Waldman - CEO

Dr. Goli Compoginis - Clinical Assistant Professor of

Dermatology at the Keck School of Medicine

Geoffrey Meacham

Jarwei Fang

View Disclosures

The English excerpt is extracted automatically from the cited source page and may contain layout or recognition errors. It is never batch translated.

Open report viewer

Related research and intelligence

Veradermics, Incorporated (MANE.N): Age subgroup analysis reinforces broad male efficacy; clean cardiac profile remains intact2026-07-17 · CitiVeradermics, Incorporated (MANE.N): Study 207 delivers robust female proof of concept; raising TP to $160 (from $135) on female opportunity2026-07-15 · CitiVeradermics, Incorporated (MANE.N): Study207 strengthens VDPHL01’s female opportunity2026-07-15 · CitiVeradermics, Incorporated (MANE.N): KOL and CEO call takeaways: Female pattern hair loss an underappreciated opportunity2026-06-25 · CitiApogee Therapeutics Inc (APGE.O): Downgrading to Neutral/HR following AbbVie acquisition announcement; TP to $135 (from $125)2026-06-22 · CitiVeradermics, Incorporated (MANE.N): Female pattern hair loss opportunity provides significant optionality; excluded from Street models2026-06-22 · Citi